O'Carrigan, B.Fournier, M.Olver, I.Stockler, M.Whitford, H.Toner, G.Thomson, D.Davis, I.Hanning, F.Singhal, N.Underhill, C.Clingan, P.Mcdonald, A.Boland, A.Grimison, P.Australian and New Zealand Urogenital and Prostate Cancer Trials Group,2015-05-192015-05-192014Internal Medicine Journal, 2014; 44(8):813-8171444-09031445-5994http://hdl.handle.net/2440/91196This is the first prospective study in a contemporary Australian/New Zealand population to determine the prevalence of testosterone deficiency in testicular cancer survivors at 12 months from treatment, and any association with poorer quality of life. Hormone assays from 54 evaluable patients in a prospective cohort study revealed biochemical hypogonadism in 18 patients (33%) and low-normal testosterone in 13 patients (24%). We found no association between testosterone levels and quality of life (all P > 0.05). Hypogonadal patients should be considered for testosterone replacement to prevent long-term morbidity.en© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicianstesticular cancer; hypogonadism; quality of lifeJournal article003001147310.1111/imj.125000003403990000162-s2.0-84905166100108255Olver, I. [0000-0001-5478-1576]